Patents Assigned to Genetics Institute
  • Patent number: 5079159
    Abstract: Eucaryotic cells cotransformed with product and selection genes yield considerably greater quantities of product after a novel subcloning strategy is employed: Transformants are identified for product yield, cultured under selection pressure and the progeny screened for product yield. Novel transformation vectors contain directly ligated selection and product genes and/or eucaryotic promoters.
    Type: Grant
    Filed: April 25, 1988
    Date of Patent: January 7, 1992
    Assignee: Genetics Institute, Inc.
    Inventor: Randal J. Kaufman
  • Patent number: 5071972
    Abstract: Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.
    Type: Grant
    Filed: October 19, 1988
    Date of Patent: December 10, 1991
    Assignee: Genetics Institute, Inc.
    Inventor: Glenn R. Larsen
  • Patent number: 5071748
    Abstract: A mixed composition polyhedral inclusion body (PIB) is provided which contains a mixture of nucleocapsids of at least two genetically distinct baculoviruses. At least one of the baculoviruses is genetically engineered to contain at least one heterologous gene. Followed ingestion of the mixed composition PIB by an insect host, a mixed viral infection ensues in the insect permitting the production therein of additional copies of the mixed composition PIB and the production of a heterologous protein encoded by the heterologous gene present in at least one of the baculoviruses.
    Type: Grant
    Filed: May 15, 1989
    Date of Patent: December 10, 1991
    Assignee: Genetics Institute, Inc.
    Inventor: David W. Miller
  • Patent number: 5055553
    Abstract: This invention relates to novel proteins useful for enhancing pulmonary surfactant activity, methods and materials for obtaining said proteins and compositions containing one or more of the proteins.
    Type: Grant
    Filed: April 9, 1990
    Date of Patent: October 8, 1991
    Assignees: Genetics Institute Inc., The Brigham & Womens Hospital, Inc.
    Inventors: Kenneth A. Jacobs, D. Randall Steinbrink, Joanna Floros, David S. Phelps, H. William Taeusch
  • Patent number: 5047345
    Abstract: A composition for isolating and purifying nucleic acid from cell culture medium and a method for isolating and purifying nucleic acid from cell culture medium employing the composition, in which the reagent includes about 1 to 3.5M acetate salt solution, about 4 to 11.2M acetic acid, about 1 to 40% by volume phenol, and about 1 to 40% by volume chloroform.
    Type: Grant
    Filed: June 2, 1989
    Date of Patent: September 10, 1991
    Assignee: Genetics Institute
    Inventors: David A. DeBonville, Gerard E. Riedel
  • Patent number: 5032395
    Abstract: An improved method for inducing leukocytosis in a primate is disclosed. The method includes co-administering IL-3 in conjunction with GM-CSF, such that the leukocyte count in the primate is synergistically raised.
    Type: Grant
    Filed: June 23, 1989
    Date of Patent: July 16, 1991
    Assignee: Genetics Institute, Inc.
    Inventors: Steven C. Clark, Agnes B. Ciarletta, Yu-Chung Yang, Robert E. Donahue
  • Patent number: 5030563
    Abstract: An improved bacterial host cell useful for the inducible production and secretion in high yields of a heterologous protein is provided which contains a gene encoding the heterologous protein operatively linked to a secretory leader-encoding sequence and to an expression control sequence which contains a promoter region; and a second DNA sequence encoding a repressor capable of binding to said promoter region. The cell contains at least a mutation in the repressor binding region of the promoter or a mutation in the promoter binding region of the repressor-encoding sequence; or mutations in both regions. These mutation(s) lower the frequency of transcriptional induction by the promoter from the observed with the wild-type promoter and/or repressor-encoding sequence, resulting in higher yields of secreted heterologous protein.
    Type: Grant
    Filed: January 26, 1990
    Date of Patent: July 9, 1991
    Assignee: Genetics Institute, Inc.
    Inventors: Paul F. Schendel, Marc Nasoff, Patricia Raney
  • Patent number: 5021239
    Abstract: Methods are presented for improving the lipoprotein cholesterol profile of a mammal. Methods are also presented for removing atherosclerotic lesions from a mammal that has such lesions. The methods comprise administering to the mammal a therapeutic amount of an M-CSF protein in combination with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: December 8, 1988
    Date of Patent: June 4, 1991
    Assignee: Genetics Institute, Inc.
    Inventor: Marc Garnick
  • Patent number: 5019509
    Abstract: This invention provides genes encoding aspartate beta decarboxylase, vectors containing the genes, microbial host cells transformed with the vectors, and the use of such transformed host cells and compositions derived therefrom to produce L-alanine and certain derivatives thereof.
    Type: Grant
    Filed: April 20, 1988
    Date of Patent: May 28, 1991
    Assignee: Genetics Institute, Inc.
    Inventor: J. David Rozzell
  • Patent number: 5019381
    Abstract: Methods are presented for lowering levels of lipoprotein cholesterol, serum cholesterol and other lipids comprising the administration of M-CSF or GM-CSF.
    Type: Grant
    Filed: March 21, 1988
    Date of Patent: May 28, 1991
    Assignee: Genetics Institute, Inc.
    Inventor: Marc Garnick
  • Patent number: 5013649
    Abstract: Purified BMP-2 proteins and processes for producing them are disclosed. They may be used in the treatment of bone and cartilage defects and in wound healing and related tissue repair.
    Type: Grant
    Filed: April 8, 1988
    Date of Patent: May 7, 1991
    Assignee: Genetics Institute, Inc.
    Inventors: Elizabeth A. Wang, John M. Wozney, Vicki Rosen
  • Patent number: 5004803
    Abstract: Hybrid procoagulant proteins are disclosed which contain peptide sequences of human blood coagulation factors V and VIII. DNA molecules encoding these proteins and materials and methods for expressing them are also disclosed. Preferably, peptide sequence in the B domain of Factor VIII is replaced with peptide sequence derived from human Factor V.
    Type: Grant
    Filed: November 14, 1988
    Date of Patent: April 2, 1991
    Assignee: Genetics Institute, Inc.
    Inventors: Randal J. Kaufman, Debra Pittman
  • Patent number: 5002887
    Abstract: Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by the presence of 0, 1, 2 or 3 N-linked polysaccharide substituents covalently bonded thereto and by a polypeptide sequence of the formula(a)A-R.sup.1 -B-R.sup.2 -C-R.sup.3 Dwherein A, B, C, and D are the following polypeptide sequences substantially as shown in FIG. 1:A is Gly-.sub.3 or Ser.sub.1 through Trp.sub.116, encompassing domain a;B is Ala.sub.120 through Gly.sub.183 ;C is Ala.sub.187 through Leu.sub.447 ;D is Val.sub.451 through Pro.sub.527 ; anda is a peptide domain comprising a sequence of 0-93 amino acids selected from the sequence Gly.sub.-3 or Ser.sub.1 through Thr.sub.91 ; R.sup.1, R.sup.2 and R.sup.3 are each a tripeptide sequence linking said A, B, C and D by peptide bonds, up to three of R.sup.1, R.sup.2 and R.sup.3 being a tripeptide sequence other than Asn-X-Thr or Asn-X-Ser, wherein X is any amino acid.
    Type: Grant
    Filed: July 3, 1986
    Date of Patent: March 26, 1991
    Assignee: Genetics Institute, Inc.
    Inventor: Glenn R. Larsen
  • Patent number: 5002874
    Abstract: Eucaryotic host cells are disclosed which contain a DNA molecule encoding an eIF-2.alpha. mutant and preferably a DNA sequence encoding a desired heterologous protein. The DNA sequences are linked to expression control sequences permitting expression of the mutant eIF-2.alpha. gene and the heterologous gene. Culturing such cells provides a method for the production of the desired heterologous protein. The mutations eliminate one or both serine residues at positions 48 and 51 of the eIF-2 sequence. In another aspect of the invention, the eIF-2 5'-untranslated sequence was observed to have effects on translation of heterologous mRNAs.
    Type: Grant
    Filed: July 30, 1990
    Date of Patent: March 26, 1991
    Assignee: Genetics Institute, Inc.
    Inventor: Randal J. Kaufman
  • Patent number: 4980165
    Abstract: Pharmaceutical formulations for intravenous bolus injection are presented that provide thrombolytic proteins, especially "second generation" tPA molecules, in relatively high concentrations at low concentrations of excipients.
    Type: Grant
    Filed: January 27, 1989
    Date of Patent: December 25, 1990
    Assignee: Genetics Institute, Inc.
    Inventors: Benjamin S. Isaacs, Himakshi Patel
  • Patent number: 4963481
    Abstract: Recombinant DNA molecules are disclosed which contain a nucleotide sequence encoding a mouse cytomegalovirus-derived transcriptional promoter. Eucaryotic host cells transformed with recombinant DNA molecules having such mouse cytomegalovirus-derived promoter sequences operatively linked to heterologous protein-coding sequences may be cultured as a method for producing the heterologous proteins or as a method for identifying and isolating DNA encoding the heterologous protein via any method involving detection of the protein.
    Type: Grant
    Filed: November 12, 1986
    Date of Patent: October 16, 1990
    Assignee: Genetics Institute Inc
    Inventor: Jean P. deVilliers
  • Patent number: 4959455
    Abstract: A novel family of primate IL-3 polypeptides is provided via recombinant techniques.
    Type: Grant
    Filed: March 4, 1987
    Date of Patent: September 25, 1990
    Assignee: Genetics Institute, Inc.
    Inventors: Steven C. Clark, Agnes B. Ciarletta, Yu-Chung Yang
  • Patent number: 4921837
    Abstract: Disclosed herein is the treatment of patients suffering from AIDS-type disease with a colony stimulating factor alone or together with erythropoietin, and/or an anti-viral agent and/or IL-2.
    Type: Grant
    Filed: July 24, 1987
    Date of Patent: May 1, 1990
    Assignee: Genetics Institute Inc.
    Inventor: Robert E. Donahue
  • Patent number: 4921796
    Abstract: This invention relates to a method for the production of a composition comprising the enzyme cyclodextrin glucosyltransferase bound by covalent means to a support material in the presence of a source of divalent calcium ion, said immobilized cyclodextrin glucosyltransferase having a higher activity and greater stability than heretofore reported. This invention further relates to the use of the immobilized cyclodextrin glucosyltransferase for the production of cyclodextrins.
    Type: Grant
    Filed: April 19, 1988
    Date of Patent: May 1, 1990
    Assignee: Genetics Institute,Inc.
    Inventor: J. David Rozzell
  • Patent number: 4918161
    Abstract: This invention relates to novel proteins useful for enhancing pulmonary surfactant activity, methods for obtaining said proteins and compositions containing one or more of the proteins.
    Type: Grant
    Filed: May 4, 1988
    Date of Patent: April 17, 1990
    Assignee: Genetics Institute, Inc.
    Inventor: D. Randall Steinbrink